Nitika Yadav, Neelottama Kushwaha, S. Kushwaha, Priyank Yadav
{"title":"传统和新型利尿剂在各种疾病中的作用","authors":"Nitika Yadav, Neelottama Kushwaha, S. Kushwaha, Priyank Yadav","doi":"10.2174/0115748855282746231208072819","DOIUrl":null,"url":null,"abstract":"\n\nDiuretics are advised as the initial course of action for hypertension because they are successful in lowering hypervolemia and resolving electrolyte abnormalities. The most popular diuretics\nare included with their main characteristics in this summary. The primary line of treatment for common cardiovascular and non-cardiovascular diseases is diuretics. Patients with hypertension, oedema,\nheart failure, as well as a variety of renal disorders are frequently treated with conventional diuretics.\nThe usage of the various types of diuretics that are now licensed for therapeutic use generally has a\nfavourable risk/benefit ratio. Nevertheless, they are not without drawbacks. Pharmaceutical scientists\nhave thus been working to develop new drugs with an enhanced pharmacological profile. SGLT2\ninhibitors (sodium-glucose-linked cotransporter 2 inhibitors) have altered how hypoglycaemic medications are thought to affect heart failure. Despite the presence or absence of diabetes, the sodiumglucose-linked cotransporter subtype 2-inhibitor class, which was first developed as a therapy for\nT2DM (Type 2 Diabetes mellitus), has shown considerable promise in lowering cardiovascular risk,\nparticularly in relation to heart failure (HF) outcomes. The immediate and substantial improvements\nobserved in clinical studies do not appear to be attributable to the drug's fundamental mechanism,\nwhich involves inducing glycosuria and diuresis by blocking receptors in the renal nephron. Among\npatients with chronic heart failure and cirrhosis, hyponatremia is a risk factor for death.\n","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of Conventional and Novel Classes of Diuretics in Various Diseases\",\"authors\":\"Nitika Yadav, Neelottama Kushwaha, S. Kushwaha, Priyank Yadav\",\"doi\":\"10.2174/0115748855282746231208072819\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nDiuretics are advised as the initial course of action for hypertension because they are successful in lowering hypervolemia and resolving electrolyte abnormalities. The most popular diuretics\\nare included with their main characteristics in this summary. The primary line of treatment for common cardiovascular and non-cardiovascular diseases is diuretics. Patients with hypertension, oedema,\\nheart failure, as well as a variety of renal disorders are frequently treated with conventional diuretics.\\nThe usage of the various types of diuretics that are now licensed for therapeutic use generally has a\\nfavourable risk/benefit ratio. Nevertheless, they are not without drawbacks. Pharmaceutical scientists\\nhave thus been working to develop new drugs with an enhanced pharmacological profile. SGLT2\\ninhibitors (sodium-glucose-linked cotransporter 2 inhibitors) have altered how hypoglycaemic medications are thought to affect heart failure. Despite the presence or absence of diabetes, the sodiumglucose-linked cotransporter subtype 2-inhibitor class, which was first developed as a therapy for\\nT2DM (Type 2 Diabetes mellitus), has shown considerable promise in lowering cardiovascular risk,\\nparticularly in relation to heart failure (HF) outcomes. The immediate and substantial improvements\\nobserved in clinical studies do not appear to be attributable to the drug's fundamental mechanism,\\nwhich involves inducing glycosuria and diuresis by blocking receptors in the renal nephron. Among\\npatients with chronic heart failure and cirrhosis, hyponatremia is a risk factor for death.\\n\",\"PeriodicalId\":11004,\"journal\":{\"name\":\"Current Drug Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2024-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Drug Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748855282746231208072819\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748855282746231208072819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Role of Conventional and Novel Classes of Diuretics in Various Diseases
Diuretics are advised as the initial course of action for hypertension because they are successful in lowering hypervolemia and resolving electrolyte abnormalities. The most popular diuretics
are included with their main characteristics in this summary. The primary line of treatment for common cardiovascular and non-cardiovascular diseases is diuretics. Patients with hypertension, oedema,
heart failure, as well as a variety of renal disorders are frequently treated with conventional diuretics.
The usage of the various types of diuretics that are now licensed for therapeutic use generally has a
favourable risk/benefit ratio. Nevertheless, they are not without drawbacks. Pharmaceutical scientists
have thus been working to develop new drugs with an enhanced pharmacological profile. SGLT2
inhibitors (sodium-glucose-linked cotransporter 2 inhibitors) have altered how hypoglycaemic medications are thought to affect heart failure. Despite the presence or absence of diabetes, the sodiumglucose-linked cotransporter subtype 2-inhibitor class, which was first developed as a therapy for
T2DM (Type 2 Diabetes mellitus), has shown considerable promise in lowering cardiovascular risk,
particularly in relation to heart failure (HF) outcomes. The immediate and substantial improvements
observed in clinical studies do not appear to be attributable to the drug's fundamental mechanism,
which involves inducing glycosuria and diuresis by blocking receptors in the renal nephron. Among
patients with chronic heart failure and cirrhosis, hyponatremia is a risk factor for death.
期刊介绍:
Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.